SB-206553
In this article, we will delve into the exciting world of SB-206553. Whether it is a person, a current topic, a historical date or any other relevant element, we will try to explore in depth different aspects related to SB-206553. In order to provide a comprehensive and enriching vision, we will address different points of view, analyze possible implications and consequences, and try to offer a critical and reflective perspective on SB-206553. We hope that this article will be of interest to those who wish to expand their knowledge on this topic and that it may spark not only new ideas, but also constructive discussions around SB-206553.
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C17H16N4O |
| Molar mass | 292.342 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
SB-206553 is a drug which acts as a mixed antagonist for the 5-HT2B and 5-HT2C serotonin receptors. It has anxiolytic properties in animal studies and interacts with a range of other drugs. It has also been shown to act as a positive allosteric modulator of α7 nicotinic acetylcholine receptors. Modified derivatives of SB-206553 have been used to probe the structure of the 5-HT2B receptor.
References
- ^ Forbes IT, Ham P, Booth DH, Martin RT, Thompson M, Baxter GS, et al. (July 1995). "5-Methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrroloindole: a novel 5-HT2C/5-HT2B receptor antagonist with improved affinity, selectivity, and oral activity". Journal of Medicinal Chemistry. 38 (14): 2524–30. doi:10.1021/jm00014a004. PMID 7629791.
- ^ Kennett GA, Wood MD, Bright F, Cilia J, Piper DC, Gager T, et al. (February 1996). "In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties". British Journal of Pharmacology. 117 (3): 427–434. doi:10.1111/j.1476-5381.1996.tb15208.x. PMC 1909304. PMID 8821530.
- ^ Forbes IT, Dabbs S, Duckworth DM, Ham P, Jones GE, King FD, et al. (December 1996). "Synthesis, biological activity, and molecular modeling of selective 5-HT(2C/2B) receptor antagonists". Journal of Medicinal Chemistry. 39 (25): 4966–77. doi:10.1021/jm960571v. PMID 8960557.
- ^ Bromidge SM, Dabbs S, Davies DT, Duckworth DM, Forbes IT, Ham P, et al. (May 1998). "Novel and selective 5-HT2C/2B receptor antagonists as potential anxiolytic agents: synthesis, quantitative structure-activity relationships, and molecular modeling of substituted 1-(3-pyridylcarbamoyl)indolines". Journal of Medicinal Chemistry. 41 (10): 1598–612. doi:10.1021/jm970741j. PMID 9572885.
- ^ Di Matteo V, Di Giovanni G, Di Mascio M, Esposito E (1998). "Selective blockade of serotonin2C/2B receptors enhances dopamine release in the rat nucleus accumbens". Neuropharmacology. 37 (2): 265–72. doi:10.1016/S0028-3908(98)00014-8. PMID 9680252. S2CID 2366196.
- ^ McCreary AC, Cunningham KA (June 1999). "Effects of the 5-HT2C/2B antagonist SB 206553 on hyperactivity induced by cocaine". Neuropsychopharmacology. 20 (6): 556–64. doi:10.1016/S0893-133X(98)00087-6. PMID 10327425.
- ^ Di Giovanni G, De Deurwaerdére P, Di Mascio M, Di Matteo V, Esposito E, Spampinato U (1999). "Selective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study". Neuroscience. 91 (2): 587–97. doi:10.1016/S0306-4522(98)00655-1. PMID 10366016. S2CID 23080031.
- ^ Takahashi RN, Berton O, Mormède P, Chaouloff F (May 2001). "Strain-dependent effects of diazepam and the 5-HT2B/2C receptor antagonist SB 206553 in spontaneously hypertensive and Lewis rats tested in the elevated plus-maze". Brazilian Journal of Medical and Biological Research. 34 (5): 675–82. doi:10.1590/s0100-879x2001000500017. PMID 11323756.
- ^ Porras G, Di Matteo V, Fracasso C, Lucas G, De Deurwaerdère P, Caccia S, et al. (March 2002). "5-HT2A and 5-HT2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum". Neuropsychopharmacology. 26 (3): 311–24. doi:10.1016/S0893-133X(01)00333-5. PMID 11850146.
- ^ Navailles S, De Deurwaerdère P, Porras G, Spampinato U (February 2004). "In vivo evidence that 5-HT2C receptor antagonist but not agonist modulates cocaine-induced dopamine outflow in the rat nucleus accumbens and striatum". Neuropsychopharmacology. 29 (2): 319–26. doi:10.1038/sj.npp.1300329. PMID 14560323.
- ^ Canal CE, Olaghere da Silva UB, Gresch PJ, Watt EE, Sanders-Bush E, Airey DC (April 2010). "The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen". Psychopharmacology. 209 (2): 163–74. doi:10.1007/s00213-010-1784-0. PMC 2868321. PMID 20165943.
- ^ Graves SM, Napier TC (June 2012). "SB 206553, a putative 5-HT2C inverse agonist, attenuates methamphetamine-seeking in rats". BMC Neuroscience. 13: 65. doi:10.1186/1471-2202-13-65. PMC 3441362. PMID 22697313.
- ^ Dunlop J, Lock T, Jow B, Sitzia F, Grauer S, Jow F, et al. (March 2009). "Old and new pharmacology: positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor by the 5-hydroxytryptamine(2B/C) receptor antagonist SB-206553 (3,5-dihydro-5-methyl-N-3-pyridinylbenzodi pyrrole-1(2H)-carboxamide)". The Journal of Pharmacology and Experimental Therapeutics. 328 (3): 766–76. doi:10.1124/jpet.108.146514. PMID 19050173. S2CID 206500076.
- ^ Kim SK, Li Y, Abrol R, Heo J, Goddard III WA (February 2011). "Predicted structures and dynamics for agonists and antagonists bound to serotonin 5-HT2B and 5-HT2C receptors". Journal of Chemical Information and Modeling. 51 (2): 420–33. doi:10.1021/ci100375b. PMC 3070210. PMID 21299232.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |